Dual-time-point 18F-FDG PET for the evaluation of gallbladder carcinoma

Journal of Nuclear Medicine

Volumn 47, Issue 4, 2006, Pages 633-638

  Nishiyama, Yoshihiro ^a   Yamamoto, Yuka ^a   Fukunaga, Kotaro ^a   Kimura, Naruhide ^a   Miki, Akihiro ^a   Sasakawa, Yasuhiro ^a   Wakabayashi, Hisao ^a   Satoh, Katashi ^a   Ohkawa, Motoomi ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

18F FDG PET; Delayed PET; Gallbladder tumor

Indexed keywords

C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; GALLBLADDER CARCINOMA; HUMAN; IMAGING SYSTEM; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIODIAGNOSIS; SENSITIVITY AND SPECIFICITY; CHOLECYSTITIS; DIFFERENTIAL DIAGNOSIS; GALLBLADDER TUMOR; MIDDLE AGED; SCINTISCANNING; WHOLE BODY COUNTING;

ADULT; AGED; AGED, 80 AND OVER; CHOLECYSTITIS; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; WHOLE-BODY COUNTING;

EID: 33745104187     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Nevin JE, Moran TJ, Kay S, et al. Carcinoma of the gallbladder: staging, treatment, and prognosis. Cancer. 1976;37:141-148.
2. Roberts JW, Daugherty SF. Primary carcinoma of the gallbladder. Surg Clin North Am. 1986;66:743-749.
3. De Aretxabala X, Roa I, Burgos L, et al. Gallbladder cancer in Chile: a report on 54 potentially resectable tumours. Cancer. 1992;69:60-65.
4. Gore RM, Yaghmai V, Newmark GM, et al. Imaging benign and malignant disease of the gallbladder. Radiol Clin North Am. 2002;40:1307-1323.
5. Grand D, Horton KM, Fishman E. CT of the gallbladder: spectrum of disease. AJR. 2004;183:163-170.
6. Yoshimitsu K, Honda H, Aibe H, et al. Radiologic diagnosis of adenomyomatosis of gallbladder: comparative study among MRI, helical CT, and transabdominal US. J Comput Assist Tomogr. 2001;25:843-850.
7. Coleman RE. Clinical PET in oncology. Clin Positron Imaging. 1998;1:15-30.
8. Anderson CD, Rice MH, Pinson W, et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangioma. J Gastrointest Surg. 2004;8:90-97.
9. 18F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology. 2001;33:1029-1035.
10. 18F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging. 2002;29:1047-1054.
11. Koh T, Taniguchi H, Yamaguchi A, et al. Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluorodeoxyglucose (FDG-PET). J Surg Oncol. 2003;84:74-81.
12. Rodriguez-Fernandez A, Gomez-Rio M, Llamas-Elvira JM, et al. Positronemission tomography with fluorine-18-fluoro-2-deoxy-D-glucose for gallbladder cancer diagnosis. Am J Surg. 2004;188:171-175.
13. Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992;33:1972-1980.
14. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412-1417.
15. Yamada S, Kubota K, Kubota R, et al. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301-1306.
16. 18F-fluoro- 2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2000;89:2547-2554.
17. 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002;43:871-875.
18. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med. 2003;44:540-548.
19. Nishiyama Y, Yamamoto Y, Monden T, et al. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl Med Commun. 2005;26:895-901.
20. Kubota K, Itoh M, Ozaki K, et al. Advantage of delayed whole-body FDG-PET imaging for tumour detection. Eur J Nucl Med. 2001;28:696-703.
21. 18F-FDG PET/CT: preliminary results for 22 patient studies. J Nucl Med. 2005;46:1158-1163.
22. Diederichs CG, Staib L, Glasbrenner B, et al. F-18 fluorodeoxyglucose (FDG) and C-reactive protein (CRP). Clin Positron Imaging. 1999;2:131-136.